Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has been given a consensus rating of “Buy” by the eight brokerages that are currently covering the firm, MarketBeat reports. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $47.50.

Several equities research analysts recently commented on the stock. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $41.00 price objective on shares of Supernus Pharmaceuticals in a research report on Tuesday, September 26th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $51.00 price objective on shares of Supernus Pharmaceuticals in a research report on Friday, August 4th. BidaskClub raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $49.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, September 27th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Supernus Pharmaceuticals in a research report on Thursday, September 21st.

In other news, CFO Gregory S. Patrick sold 50,000 shares of the company’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $47.60, for a total value of $2,380,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Padmanabh P. Bhatt sold 3,709 shares of the company’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total transaction of $167,758.07. Following the completion of the sale, the vice president now directly owns 17,500 shares in the company, valued at $791,525. The disclosure for this sale can be found here. Insiders have sold a total of 153,709 shares of company stock worth $7,223,108 over the last three months. Insiders own 6.70% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. raised its holdings in shares of Supernus Pharmaceuticals by 0.5% in the 2nd quarter. BlackRock Inc. now owns 6,727,641 shares of the specialty pharmaceutical company’s stock valued at $289,962,000 after purchasing an additional 31,331 shares during the period. Vanguard Group Inc. raised its holdings in shares of Supernus Pharmaceuticals by 39.1% in the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock valued at $150,873,000 after purchasing an additional 984,200 shares during the period. Ranger Investment Management L.P. raised its holdings in shares of Supernus Pharmaceuticals by 2.8% in the 1st quarter. Ranger Investment Management L.P. now owns 1,482,535 shares of the specialty pharmaceutical company’s stock valued at $46,403,000 after purchasing an additional 40,131 shares during the period. State Street Corp raised its holdings in shares of Supernus Pharmaceuticals by 3.1% in the 2nd quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock valued at $60,230,000 after purchasing an additional 42,165 shares during the period. Finally, Rice Hall James & Associates LLC raised its holdings in shares of Supernus Pharmaceuticals by 24.5% in the 2nd quarter. Rice Hall James & Associates LLC now owns 1,361,373 shares of the specialty pharmaceutical company’s stock valued at $58,675,000 after purchasing an additional 267,971 shares during the period. 95.36% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Supernus Pharmaceuticals, Inc. (SUPN) Receives Consensus Rating of “Buy” from Analysts” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/11/supernus-pharmaceuticals-inc-supn-receives-consensus-rating-of-buy-from-analysts.html.

Supernus Pharmaceuticals (NASDAQ SUPN) traded up 0.24% during mid-day trading on Wednesday, hitting $41.20. The stock had a trading volume of 331,691 shares. The company has a 50-day moving average price of $43.59 and a 200 day moving average price of $39.23. The company has a market cap of $2.09 billion, a P/E ratio of 20.60 and a beta of 1.30. Supernus Pharmaceuticals has a 1-year low of $17.25 and a 1-year high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.24 by $0.08. The business had revenue of $75.83 million for the quarter, compared to analysts’ expectations of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. Equities research analysts forecast that Supernus Pharmaceuticals will post $1.04 EPS for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.